Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jun 25;16(1):140.
doi: 10.1186/s13098-024-01369-x.

Emerging insights into the role of IL-1 inhibitors and colchicine for inflammation control in type 2 diabetes

Jianbin Guan  1 , Haimiti Abudouaini  1 , Kaiyuan Lin  2 , Kaitan Yang  3   4
Affiliations
Review

Emerging insights into the role of IL-1 inhibitors and colchicine for inflammation control in type 2 diabetes

Jianbin Guan et al. Diabetol Metab Syndr. .

Retraction in

Abstract

Type 2 diabetes mellitus (T2DM), a prevalent chronic metabolic disorder, is closely linked to persistent low-grade inflammation, significantly contributing to its development and progression. This review provides a comprehensive examination of the inflammatory mechanisms underlying T2DM, focusing on the role of the NLRP3 inflammasome and interleukin-1β (IL-1β) in mediating inflammatory responses. We discuss the therapeutic potential of IL-1 inhibitors and colchicine, highlighting their mechanisms in inhibiting the NLRP3 inflammasome and reducing IL-1β production. Recent studies indicate that these agents could effectively mitigate inflammation, offering promising avenues for the prevention and management of T2DM. By exploring the intricate connections between metabolic disturbances and chronic inflammation, this review underscores the need for novel anti-inflammatory strategies to address T2DM and its complications.

Keywords: Chronic inflammation; Colchicine; IL-1 inhibitors; NLRP3 inflammasome; Type 2 Diabetes (T2DM).

PubMed Disclaimer

Conflict of interest statement

All authors declare no conflict of interest.

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Effects of IL-1 blocker on inflammatory markers and glucose metabolism
Fig. 2
Fig. 2
Anti-inflammatory mechanisms of colchicine
See this image and copyright information in PMC

References

    1. Ong KL, Stafford LK, McLaughlin SA, et al. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the global burden of disease study 2021. Lancet. 2023;402:203–34. - DOI - PMC - PubMed
    1. Tabák AG, Herder C, Rathmann W, et al. Prediabetes: a high-risk state for diabetes development. Lancet. 2012;379:2279–90. - DOI - PMC - PubMed
    1. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403. - DOI - PMC - PubMed
    1. American Diabetes Association. 2. Classification and diagnosis of diabetes: Standards of medical care in diabetes-2021. Diabetes Care. 2021; 44: S15–S33. - PubMed
    1. Schmidt MI, Duncan BB, Sharrett AR, et al. Markers of inflammation and prediction of diabetes mellitus in adults (atherosclerosis risk in communities study): a cohort study. Lancet. 1999;353:1649–52. - DOI - PubMed

LinkOut - more resources